Find and Pitch Jounalists, Get Your Story Covered

Tags: hardware robotics startups funding industrial robotics

	Profile	Recent Articles on Subject
1	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Up and down the ladder: The latest comings and goings - 27 days ago STAT+: Up and down the ladder: The latest comings and goings - 3 months ago STAT+: Up and down the ladder: The latest comings and goings - 4 months ago STAT+: Up and down the ladder: The latest comings and goings - 5 months ago STAT+: Pharmalittle: We’re reading about GSK leaving BIO, an AbbVie schizophrenia drug failing, and more - 5 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Pharmalittle: We’re reading about pharma risks in China, mitigating shortages, and more - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 6 months ago STAT+: Up and down the ladder: The latest comings and goings - 7 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 8 months ago STAT+: Up and down the ladder: The latest comings and goings - 9 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: U.K. trade group scolds Novo, Novartis, Pfizer, and Otsuka for violating industry codes - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 10 months ago STAT+: Up and down the ladder: The latest comings and goings - 12 months ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Pharmalittle: We’re reading about biotech startups, Pfizer’s RSV vaccine, and more - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - about 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Pharmalittle: We’re reading about Lilly selling drugs directly, UCB leaving BIO, and more news - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and Down the Ladder: The latest comings and goings - over 1 year ago STAT+: Pharmalittle: Pharma moves closer to a pricing deal with U.K.; FDA to review AstraZeneca request for self-administered flu vax - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago STAT+: Up and down the ladder: The latest comings and goings - over 1 year ago
2	Michael Gibney Pharma Voice Teacher of English. Teacher of politics. Santiago, Chile educationpolitics	With uncertainty roiling Big Pharma, execs are placing lower-risk bets - 3 months ago Will 2025 mark pharma’s pivot to bigger deals after years of lackluster M&A? - 3 months ago How pharma was instrumental in President Jimmy Carter’s global health efforts - 4 months ago Why pharma megamergers may become a relic of the past - 6 months ago Top pharma and biotech conferences 2025 - 7 months ago Market share shakeup: Big Pharma’s bestselling drugs drive industry shifts in 2024’s first half - 9 months ago Has pharma emerged from the ‘age of uncertainty’? - 9 months ago Don’t call it a comeback: Biotech’s CNS resurgence forges Big Pharma connections - 10 months ago As Big Pharma places bigger bets on ADCs, here’s where the field is headed next - 11 months ago AstraZeneca’s $80B sales goal by 2030 reflects industry’s penchant for long-term bets - 11 months ago How pharma’s surging M&A is impacting the industry’s tech sector - about 1 year ago Pharma’s financial market will be a tale of two cities in 2024 - over 1 year ago Biopharma’s FTC headache deepens with guideline shifts years in the making - over 1 year ago The thorniest questions facing pharma, according to a leading bioethicist - over 1 year ago How Big Pharma keeps the oncology engines hot with a host of strategies - over 1 year ago
3	Meagan Parrish Pharma Voice Senior editor @industrydive. Pharma world follower. Wisconsin, USA pharmaceuticalsjournalismparenting	As financial headwinds pick up, pharmas are aiming to squeeze more ROI from their R&D - 3 months ago Pharma’s forecast for 2025: Sowing seeds of a rebound - 3 months ago PharmaVoice’s Crystal Ball: The industry’s AI future - 4 months ago 3 closely watched drugs that failed in the clinic - 4 months ago Pharma takes aim at a wily foe — the Epstein-Barr virus - 6 months ago 2024 PharmaVoice 100s: Trailblazers - 6 months ago What 3 layoff stories reveal about pharma’s troubles - 8 months ago Pharma’s R&D gamble: picking pipeline winners in a risky field - 11 months ago Where competition is heating up in pharma - 11 months ago The biggest questions hanging over pharma in 2024 - about 1 year ago PharmaVoice’s Crystal Ball: What’s next in drug innovation and clinical trials - over 1 year ago PharmaVoice 100s: Entrepreneurs - over 1 year ago PharmaVoice 100s: Clinical trial gurus - over 1 year ago
4	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	From Mr. Mucus to the Super Bowl, pharma tries offbeat marketing strategies - 5 months ago M&A is ready to explode, and that’s good news for pharma layoffs - 8 months ago As the GLP-1 market booms, other healthcare companies are cashing in - 10 months ago Pfizer and Lilly are elbowing into the direct-to-consumer market. Will it work? - 11 months ago
5	Pharmacy Times Pharmacy Times #pharmacy news, insights. CE provider. Cranbury, New Jersey pharmacyhealthcarejournalism	Unmasking Health Care Fraud: RICO Is Increasingly Being Used in the Pharmaceutical Industry - 6 months ago
6	Beth Mole Ars Technica Senior Health Reporter @ArsTechnica. microbiologyinfectious diseasespublic health	Big Pharma spends billions more on executives and stockholders than on R&D - about 1 year ago
7	Mike Hennessy Jr, President and CEO Pharmacy Times Pro middleweight boxer. UK/Ireland. BoxingSports	Pharmacists Are Vital to Heart Health - about 1 year ago
8	PharmaTimes PharmaTimes PharmaTimes Media Ltd. Digital health news. Surrey, United Kingdom pharmahealthdigital healthmhealthNHSmarketingcommunicationsclinicaljobsMSL	2024 - over 1 year ago
9	Nicholas Florko STAT News Reports on US health business. Washington, DC healthcarepolicy	STAT+: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny - over 1 year ago
10	Kelly Bilodeau Pharma Voice Mom, wife, freelance writer. writing	What are pharma’s next blockbusters? - over 1 year ago Oncology drugmakers seek the sweet spot between efficacy and tolerability - over 1 year ago From the rainforest to Wall Street — Jaguar Health’s big play for revitalization - over 1 year ago

Journalists covering pharmaceutical industry